Bicycle Therapeutics Profit Margin 2018-2021 | BCYC

Current and historical gross margin, operating margin and net profit margin for Bicycle Therapeutics (BCYC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bicycle Therapeutics net profit margin as of September 30, 2021 is -562.38%.
Bicycle Therapeutics Annual Profit Margins
Bicycle Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.529B $0.010B
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $6.887B 0.00
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71